Microvascular Dysfunction Doubles Heart Disease Risk Even Without Blocked Arteries
New research shows coronary microvascular dysfunction sharply raises cardiac event risk, even in patients without obstructive artery disease.
Summary
Coronary microvascular dysfunction (CMD) — a condition affecting the tiny blood vessels of the heart — significantly raises the risk of serious cardiac events, even when major arteries appear clear. A large prospective Korean study of over 1,000 patients found that CMD nearly doubled two-year risk of death, heart attack, or hospitalization. Most strikingly, CMD patients without obstructive coronary artery disease faced over three times the risk of those without CMD. The findings, published in The Lancet, suggest that standard coronary angiography may miss an important driver of heart disease. Currently, no targeted therapy for CMD exists, though managing underlying causes like atherosclerosis with statins is recommended. Researchers urge further studies to determine whether directly treating CMD can improve outcomes.
Detailed Summary
Coronary microvascular dysfunction (CMD) has long been considered a secondary concern in cardiology, overshadowed by the more visible problem of blocked major arteries. New research presented at the EuroPCR conference and published in The Lancet is now challenging that hierarchy, positioning CMD as a significant, independent contributor to serious heart disease outcomes.
The FLOW-CMD registry, a prospective observational study spanning seven Korean medical centers, enrolled over 1,000 consecutive patients referred for invasive coronary angiography between 2022 and 2024. Researchers comprehensively assessed both epicardial coronary artery disease and microvascular function to understand how each independently contributed to patient outcomes over two years.
The headline finding was striking: patients with CMD faced an 18.8% estimated two-year risk of a composite endpoint — including death, heart attack, repeat revascularization, or heart failure hospitalization — compared to just 10.5% in those without CMD. That translates to a hazard ratio of 1.91, nearly doubling risk. Even more alarming, CMD patients without obstructive artery disease had a hazard ratio of 3.45, suggesting microvascular disease may be especially dangerous precisely when traditional testing finds nothing wrong.
CMD also correlated with worse chest pain symptoms after coronary stenting procedures, consistent with earlier research suggesting it underlies persistent angina in patients whose major arteries have been treated. This has real clinical implications: patients who continue experiencing chest pain after successful stent placement may be suffering from unaddressed microvascular disease.
However, significant gaps remain. No approved therapy specifically targets CMD. The WARRIOR trial last year failed to show that statins combined with blood pressure medications prevented major cardiac events in women with suspected ischemia and no obstructive disease, though poor adherence and COVID-related disruptions clouded those results. Researchers call for dedicated treatment trials. For now, identifying CMD may at least help explain symptoms and guide holistic cardiovascular risk management.
Key Findings
- CMD nearly doubled 2-year risk of death, heart attack, or heart failure hospitalization versus no CMD.
- CMD without obstructive artery disease carried over 3x the cardiac event risk compared to patients without CMD.
- CMD was common even alongside obstructive coronary artery disease, affecting 21.5% of that group.
- Patients with CMD had persistently worse chest pain after coronary stenting, suggesting an unaddressed mechanism.
- No proven targeted therapy for CMD currently exists; managing underlying causes like atherosclerosis is the current approach.
Methodology
This is a meeting coverage news report summarizing a prospective, observational registry study published simultaneously in The Lancet, a high-credibility peer-reviewed journal. The FLOW-CMD study enrolled over 1,000 consecutive patients across seven Korean sites, providing a real-world, unselected patient population. As an observational study, it demonstrates association rather than causation and cannot confirm that treating CMD would improve outcomes.
Study Limitations
The study is observational and conducted exclusively in Korean patients, which may limit generalizability to other ethnic populations. No randomized controlled trial yet confirms that identifying or treating CMD improves hard clinical outcomes. The article text was truncated, so full methodological details, including exact CMD diagnostic criteria and baseline patient characteristics, should be verified in the primary Lancet publication.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.